Studying a new drug combo for recurrent ovarian cancer after prior treatments
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemotherapy.
- You must have received 1 to 3 prior lines of platinum-based chemotherapy, and your cancer must have returned more than 6 months after the last treatment.
- You must have previously been treated with a PARP inhibitor (a type of targeted therapy).
- You must have a tumor that can be measured on scans, and you must be in reasonably good health (ECOG performance status 0 or 1).
- You must not have certain cancer types (clear cell, low-grade serous, or mucinous) and must not have untreated or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.